Harmony Biosciences (HRMY) Competitors

BridgeBio Pharma (NASDAQ:BBIO) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability, community ranking and analyst recommendations.

Do institutionals and insiders believe in BBIO or HRMY?

99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 24.7% of BridgeBio Pharma shares are owned by insiders. Comparatively, 23.6% of Harmony Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is BBIO or HRMY more profitable?

Harmony Biosciences has a net margin of 17.98% compared to BridgeBio Pharma's net margin of -241.44%. Harmony Biosciences' return on equity of 23.16% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-241.44%	N/A	-75.69%
Harmony Biosciences	17.98%	23.16%	14.24%

Does the media refer more to BBIO or HRMY?

In the previous week, BridgeBio Pharma had 11 more articles in the media than Harmony Biosciences. MarketBeat recorded 21 mentions for BridgeBio Pharma and 10 mentions for Harmony Biosciences. Harmony Biosciences' average media sentiment score of 1.22 beat BridgeBio Pharma's score of 0.91 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	9 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	5 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, BBIO or HRMY?

Harmony Biosciences has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$221.90M	30.05	-$535.76M	-$2.85	-12.30
Harmony Biosciences	$714.73M	2.33	$128.85M	$2.51	11.57

Does the MarketBeat Community favor BBIO or HRMY?

BridgeBio Pharma received 110 more outperform votes than Harmony Biosciences when rated by MarketBeat users. Likewise, 72.13% of users gave BridgeBio Pharma an outperform vote while only 70.97% of users gave Harmony Biosciences an outperform vote.

Company	Underperform	Outperform
BridgeBio Pharma	Outperform Votes 176 72.13%	Underperform Votes 68 27.87%
Harmony Biosciences	Outperform Votes 66 70.97%	Underperform Votes 27 29.03%

Do analysts recommend BBIO or HRMY?

BridgeBio Pharma currently has a consensus price target of $53.00, indicating a potential upside of 51.19%. Harmony Biosciences has a consensus price target of $53.33, indicating a potential upside of 83.65%. Given Harmony Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Harmony Biosciences is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	0 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.92
Harmony Biosciences	0 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk & volatility, BBIO or HRMY?

BridgeBio Pharma has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Harmony Biosciences has a beta of 0.8, suggesting that its stock price is 20% less volatile than the S&P 500.

Summary

Harmony Biosciences beats BridgeBio Pharma on 10 of the 18 factors compared between the two stocks.